Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LA3IK
- Development stage
- Preclinical
- Lead developer
- University of North Texas Health Science Center
- Modality
- Peptides
- Administration
- Intraperitoneal, Intravenous
01
Overview
LA3IK is a first-in-class, MIEN1-based hexapeptide (chemically identified as Ac-LAIAVK-NH2) developed by the University of North Texas Health Science Center. Derived from the conserved regions of the Migration and Invasion Enhancer 1 (MIEN1) protein, LA3IK acts as a therapeutic peptide designed to inhibit cancer cell migration, invasion, and epithelial-to-mesenchymal transition (EMT). Mechanistically, LA3IK binds to MIEN1 and disrupts Epidermal Growth Factor (EGF)-driven oncogenic signaling. Specifically, it selectively interferes with the heterodimerization of Epidermal Growth Factor Receptor (EGFR) and ERBB2 (HER2), thereby reducing EGFR phosphorylation and suppressing downstream signaling pathways involving NF-κB, Src, and STAT3. LA3IK has demonstrated preclinical efficacy in breast, prostate, and colorectal cancer models, with its D-isomer (D-LA3IK) showing enhanced stability and pharmacokinetic properties.
- Other names
- Ac-LAIAVK-NH2Ac-LAIAVK-NH-2Ac-LAIAVK-NH 2D-LA3IKD-LA-3IKD-LA 3IKLAIAVK
02
Targets
MIEN1 (Migration and invasion enhancer 1)
Beyond the preview
Go deeper on LA3IK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LA3IK.